Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer

Clin Exp Metastasis. 2020 Apr;37(2):293-304. doi: 10.1007/s10585-020-10024-4. Epub 2020 Feb 1.

Abstract

Most women with epithelial ovarian cancer (EOC) suffer from peritoneal carcinomatosis upon first clinical presentation. Extensive peritoneal carcinomatosis has a poor prognosis and its pathophysiology is not well understood. Although treatment with systemic intravenous chemotherapy is often initially successful, peritoneal recurrences occur regularly. We hypothesized that insufficient or poorly-perfused microvasculature may impair the therapeutic efficacy of systemic intravenous chemotherapy but may also limit expansive and invasive growth characteristic of peritoneal EOC metastases. In 23 patients with advanced EOC or suspicion thereof, we determined the angioarchitecture and perfusion of the microvasculature in peritoneum and in peritoneal metastases using incident dark field (IDF) imaging. Additionally, we performed immunohistochemical analysis and 3-dimensional (3D) whole tumor imaging using light sheet fluorescence microscopy of IDF-imaged tissue sites. In all metastases, microvasculature was present but the angioarchitecture was chaotic and the vessel density and perfusion of vessels was significantly lower than in unaffected peritoneum. Immunohistochemical analysis showed expression of vascular endothelial growth factor and hypoxia inducible factor 1α, and 3D imaging demonstrated vascular continuity between metastases and the vascular network of the peritoneum beneath the elastic lamina of the peritoneum. We conclude that perfusion of the microvasculature within metastases is limited, which may cause hypoxia, affect the behavior of EOC metastases on the peritoneum and limit the response of EOC metastases to systemic treatment.

Keywords: EOC; Incident dark field imaging; Microcirculation; Microvasculature; Peritoneal carcinomatosa.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Ovarian Epithelial / blood supply*
  • Carcinoma, Ovarian Epithelial / secondary
  • Carcinoma, Ovarian Epithelial / therapy
  • Cell Hypoxia
  • Chemotherapy, Adjuvant
  • Cytoreduction Surgical Procedures
  • Female
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / analysis
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Imaging, Three-Dimensional
  • Immunohistochemistry
  • Microvessels / diagnostic imaging*
  • Microvessels / pathology
  • Middle Aged
  • Neoadjuvant Therapy
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*
  • Ovariectomy
  • Ovary / pathology
  • Ovary / surgery
  • Peritoneal Neoplasms / blood supply*
  • Peritoneal Neoplasms / prevention & control
  • Peritoneal Neoplasms / secondary
  • Peritoneum / blood supply
  • Peritoneum / pathology*
  • Prospective Studies
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / analysis
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Antineoplastic Agents
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A